KRAS and colorectal carcinoma: Therefore, the focus should be placed more on exploring the use of these inhibitors in combination with other inhibitors of the MAPK pathway or with other inhibitors that we mentioned in this Review, which may bring surprise for the treatment of KRAS-mutant CRC.